Dominique Fontanilla, Laurie Withington, Stephanie Yip, Pammy Spicer, and Mike Ramirez discuss current events in the healthcare space in the Informa Pharma Intelligence Podcast.

Topics covered in this episode include:

• Clinical trial data from AAN are highlighted for Biogen’s Spinraza, Novartis’ gene therapy Zolgensma, and Roche’s risdiplam in spinal muscular atrophy. In addition, discussion points included in this segment are the potential market competition between the three drugs, differentiating factors, and possible barriers to uptake. (1:46)

• Data presented on a new class of oral CGRP receptor antagonists by Allergan with ubrogepant and atogepant, in acute and episodic migraine respectively, as well as Biohaven’s rimegepant (ODT and tablet) in acute migraine. Efficacy and safety data are analyzed between the drugs, as well as currently approved treatments, as the companies approach filing and/or approval for acute migraine treatment. (18:55)

• Long-term data showing sustained effects from the PROMISE-1 and PROMISE-2 trials investigating Alder BioPharmaceuticals’ lead drug candidate, eptinezumab, as a preventive for migraine. Eptinezumab’s competitive position within the context of marketed anti-CGRPs and other traditional preventive migraine therapies is discussed. (35:09)

• A comparative discussion of neuromyelitis optica spectrum disorder candidates Soliris, satralizumab, and inebilizumab are discussed in the context of sub-group results presented at AAN. (51:21)

To learn more about Datamonitor Healthcare, Citeline, and other offerings from Informa Pharma Intelligence, visit:

pharmaintelligence.informa.com/